From the PR Newswires/First Call version:
. . . .Merck today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Elonva® (corifollitropin alfa injection) as a treatment in controlled ovarian stimulation in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology program. . . .
To be fair, Merck has a dense forest of tremendously-thick-trunked trees , for its newly-combined science programs -- and these will continue to drop a significant bevy of acorns.
No comments:
Post a Comment